Protagonist Therapeutics Inc annual revenue for fiscal TTM was $282 million, an increase of 513.0% from $46 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Revenue (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $282M | $46M | $434M | $60M | $27M | $27M | $29M | $0M | $31M | $20M | $0M | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Revenue (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $214M | $56M | $7M | $5M | $6M | $28M | $171M | $5M | $4M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More PTGX metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All PTGX financial statements → Interactive PTGX charts →
About TickerBase · Data methodology & sources · Privacy · Terms